This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| European Union In Vitro Diagnostic Regulation | |
|---|---|
| Name | In Vitro Diagnostic Regulation |
| Jurisdiction | European Union |
| Enacted | 2017 |
| Commenced | 2017 |
| Status | in force |
European Union In Vitro Diagnostic Regulation The In Vitro Diagnostic Regulation is a European Regulation (European Union) enacted in 2017 to govern the placing on the market, performance, and safety of in vitro diagnostic medical devices across the European Union. It replaces the previous Directive 98/79/EC framework with a directly applicable Regulation (European Union) No 2017/746 designed to strengthen conformity assessment, market surveillance, and clinical performance requirements for devices used in laboratory diagnostics, public health, and companion diagnostics. The measure interacts with institutions such as the European Commission, European Medicines Agency, and national competent authorities across member states.
The regulation developed amid high-profile incidents in Europe and beyond that exposed weaknesses in device oversight, prompting legislative reform within the European Commission and debates in the European Parliament and Council of the European Union. It followed reform trajectories similar to the Medical Device Regulation discussions and drew input from stakeholders including the European Centre for Disease Prevention and Control, World Health Organization, and national authorities like Bundesinstitut für Arzneimittel und Medizinprodukte and Agence nationale de sécurité du médicament et des produits de santé. Negotiations referenced standards from International Organization for Standardization and harmonisation work of the Global Harmonization Task Force. The final act was adopted by the Council of the European Union and the European Parliament and signed into law by the European Commission in 2017.
The regulation defines "in vitro diagnostic medical devices" and distinguishes device types using criteria aligned with international taxonomies developed by organizations such as International Medical Device Regulators Forum and ISO. It clarifies applicability to devices used in clinical laboratories linked to institutions like Charité – Universitätsmedizin Berlin or Great Ormond Street Hospital and to companion diagnostics used alongside medicinal products authorised by the European Medicines Agency. Exemptions and specific provisions reference public health instruments including International Health Regulations and programmes managed by the European Centre for Disease Prevention and Control.
The framework introduces a risk-based classification system that reclassifies certain device categories and increases requirements for high-risk items, mirroring approaches used by United States Food and Drug Administration and regulatory models from Health Canada. Classification rules determine the applicable conformity assessment route, involving standards promulgated by European Committee for Standardization and technical guidance from the European Commission. Devices require technical documentation, quality management systems often compliant with ISO 13485, and performance evaluation plans comparable to evidence demanded by regulatory agencies such as the Therapeutic Goods Administration.
The regulation tightens designation and monitoring of notified bodies, the conformity assessment organizations designated under member state authority such as Bureau Veritas or national notified bodies like BSI Group and TÜV SÜD. Oversight includes joint assessment processes involving the European Commission and national competent authorities, and aims to address earlier criticisms raised in inquiries involving notified body performance. Accreditation bodies such as European co-operation for Accreditation play roles in designation. Transparency mechanisms require publication of notified body scope and corrective actions akin to practices in United States Food and Drug Administration inspections.
Stronger post-market surveillance and vigilance obligations oblige manufacturers to implement proactive surveillance systems drawing on databases and networks such as the European Databank on Medical Devices and information exchange with public health authorities including European Centre for Disease Prevention and Control. The regulation mandates periodic safety update reports and incident reporting comparable to frameworks in Japan Pharmaceuticals and Medical Devices Agency and incident registries maintained by large healthcare providers like Karolinska University Hospital. National competent authorities must coordinate recalls and field safety corrective actions within forums involving the European Commission.
Clinical performance and scientific validity requirements increased substantially, obliging manufacturers to generate evidence from studies, comparative performance investigations, and real-world data sources such as registries maintained by centres like Mayo Clinic or Johns Hopkins Hospital. The regulation sets out criteria for analytical performance, clinical performance, and scientific validity drawing on methodologies endorsed by International Medical Device Regulators Forum and standards from International Organization for Standardization. For companion diagnostics, interaction with marketing authorisation holders regulated by the European Medicines Agency is specified.
The regulation included transitional timelines to phase out legacy devices authorised under Directive 98/79/EC and to allow re-certification by notified bodies; these transitions involved coordination with national competent authorities such as Haute Autorité de Santé and Medicines and Healthcare products Regulatory Agency. Member states are responsible for enforcement measures, penalties, and market surveillance actions analogous to national regulatory activity by Bundesinstitut für Arzneimittel und Medizinprodukte and Agenzia Italiana del Farmaco. Ongoing implementation challenges have prompted stakeholder engagement with organisations such as European Federation of Pharmaceutical Industries and Associations and professional societies including European Society of Clinical Microbiology and Infectious Diseases.